301 related articles for article (PubMed ID: 33816289)
41. Modulation of gut microbiota: a novel approach to enhancing the effects of immune checkpoint inhibitors.
Huang J; Gong C; Zhou A
Ther Adv Med Oncol; 2023; 15():17588359231204854. PubMed ID: 37841750
[TBL] [Abstract][Full Text] [Related]
42. Modulation of the gut microbiome: a systematic review of the effect of bariatric surgery.
Guo Y; Huang ZP; Liu CQ; Qi L; Sheng Y; Zou DJ
Eur J Endocrinol; 2018 Jan; 178(1):43-56. PubMed ID: 28916564
[TBL] [Abstract][Full Text] [Related]
43. Antibiotics and immunotherapy in gastrointestinal tumors: Friend or foe?
Yan C; Tu XX; Wu W; Tong Z; Liu LL; Zheng Y; Jiang WQ; Zhao P; Fang WJ; Zhang HY
World J Clin Cases; 2019 Jun; 7(11):1253-1261. PubMed ID: 31236389
[TBL] [Abstract][Full Text] [Related]
44. Analysis of the Gut Microbiome of Rural and Urban Healthy Indians Living in Sea Level and High Altitude Areas.
Das B; Ghosh TS; Kedia S; Rampal R; Saxena S; Bag S; Mitra R; Dayal M; Mehta O; Surendranath A; Travis SPL; Tripathi P; Nair GB; Ahuja V
Sci Rep; 2018 Jul; 8(1):10104. PubMed ID: 29973712
[TBL] [Abstract][Full Text] [Related]
45. The effect of antibiotics on the clinical outcomes of patients with solid cancers undergoing immune checkpoint inhibitor treatment: a retrospective study.
Kim H; Lee JE; Hong SH; Lee MA; Kang JH; Kim IH
BMC Cancer; 2019 Nov; 19(1):1100. PubMed ID: 31718585
[TBL] [Abstract][Full Text] [Related]
46. Effect of microbiome group on immune checkpoint inhibitors in treatment of gastrointestinal tumors.
Pei B; Ma X; Wu N; Wang C; Yang W
Chin J Cancer Res; 2023 Jun; 35(3):252-265. PubMed ID: 37440825
[TBL] [Abstract][Full Text] [Related]
47. Altered Composition of Gut Microbiota in Depression: A Systematic Review.
Barandouzi ZA; Starkweather AR; Henderson WA; Gyamfi A; Cong XS
Front Psychiatry; 2020; 11():541. PubMed ID: 32587537
[TBL] [Abstract][Full Text] [Related]
48. Gut Microbiome and the Response to Immunotherapy in Cancer.
Stancu AL
Discoveries (Craiova); 2018 Sep; 6(3):e84. PubMed ID: 32309602
[TBL] [Abstract][Full Text] [Related]
49. Associations between Diet, the Gut Microbiome, and Short-Chain Fatty Acid Production among Older Caribbean Latino Adults.
Maldonado-Contreras A; Noel SE; Ward DV; Velez M; Mangano KM
J Acad Nutr Diet; 2020 Dec; 120(12):2047-2060.e6. PubMed ID: 32798072
[TBL] [Abstract][Full Text] [Related]
50. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
51. Predictive Biomarkers for Outcomes of Immune Checkpoint Inhibitors (ICIs) in Melanoma: A Systematic Review.
Baltussen JC; Welters MJP; Verdegaal EME; Kapiteijn E; Schrader AMR; Slingerland M; Liefers GJ; van der Burg SH; Portielje JEA; de Glas NA
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944986
[TBL] [Abstract][Full Text] [Related]
52. Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer.
Zhao S; Gao G; Li W; Li X; Zhao C; Jiang T; Jia Y; He Y; Li A; Su C; Ren S; Chen X; Zhou C
Lung Cancer; 2019 Apr; 130():10-17. PubMed ID: 30885328
[TBL] [Abstract][Full Text] [Related]
53. Metatranscriptomic analysis to define the Secrebiome, and 16S rRNA profiling of the gut microbiome in obesity and metabolic syndrome of Mexican children.
Gallardo-Becerra L; Cornejo-Granados F; García-López R; Valdez-Lara A; Bikel S; Canizales-Quinteros S; López-Contreras BE; Mendoza-Vargas A; Nielsen H; Ochoa-Leyva A
Microb Cell Fact; 2020 Mar; 19(1):61. PubMed ID: 32143621
[TBL] [Abstract][Full Text] [Related]
54. Impact of Age, Caloric Restriction, and Influenza Infection on Mouse Gut Microbiome: An Exploratory Study of the Role of Age-Related Microbiome Changes on Influenza Responses.
Bartley JM; Zhou X; Kuchel GA; Weinstock GM; Haynes L
Front Immunol; 2017; 8():1164. PubMed ID: 28979265
[TBL] [Abstract][Full Text] [Related]
55. Adaptation of gut microbiome to different dietary nonstarch polysaccharide fractions in a porcine model.
Tian G; Wu X; Chen D; Yu B; He J
Mol Nutr Food Res; 2017 Oct; 61(10):. PubMed ID: 28586175
[TBL] [Abstract][Full Text] [Related]
56. Impact of BMI on Survival Outcomes of Immunotherapy in Solid Tumors: A Systematic Review.
Indini A; Rijavec E; Ghidini M; Tomasello G; Cattaneo M; Barbin F; Bareggi C; Galassi B; Gambini D; Grossi F
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33807855
[TBL] [Abstract][Full Text] [Related]
57. Impact of bowel movement condition on immune checkpoint inhibitor efficacy in patients with advanced non-small cell lung cancer.
Katayama Y; Yamada T; Tanimura K; Yoshimura A; Takeda T; Chihara Y; Tamiya N; Kaneko Y; Uchino J; Takayama K
Thorac Cancer; 2019 Mar; 10(3):526-532. PubMed ID: 30666802
[TBL] [Abstract][Full Text] [Related]
58. Efficacy and regulatory strategies of gut microbiota in immunotherapy: a narrative review.
Sang Y; Zheng K; Zhao Y; Liu Y; Zhu S; Xie X; Shang L; Liu J; Li L
Transl Cancer Res; 2024 Apr; 13(4):2043-2063. PubMed ID: 38737692
[TBL] [Abstract][Full Text] [Related]
59. Gut microbiota diversity and composition in predicting immunotherapy response and immunotherapy-related colitis in melanoma patients: A systematic review.
Oey O; Liu YY; Sunjaya AF; Simadibrata DM; Khattak MA; Gray E
World J Clin Oncol; 2022 Nov; 13(11):929-942. PubMed ID: 36483977
[TBL] [Abstract][Full Text] [Related]
60. [Tracking Research Progress in the Modulatory Role of Gut Microbiome in Immune Checkpoint Inhibitors Applied in Cancer Treatment].
Wu MR; Tang MY; Zheng BH; Zhou ST
Sichuan Da Xue Xue Bao Yi Xue Ban; 2021 Sep; 52(5):735-739. PubMed ID: 34622585
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
